J-CODE
J3299
DESCRIPTION: Injection, Triamcinolone Acetonide (Xipere), 1 mg
EFFECTIVE: July 1, 2022

Billing and Coding Resources

Letters of Medical Necessity PDF Letters of Medical Necessity Download
Coding + Billing Checklist pdg Coding & Billing Checklist Download
Sample Claim Form pdf Sample Claim Form Download
Billing and Coding Guide pdf Billing & Coding Guide Download
FOA Program Enrollment Form pdf FOA Program Enrollment Form Download

Training Resources

How to Order Leave Behind PDF How to Order Leave Behind Download
Injection Training Video Injection Training Video Download
X
Instructions for Use pdf Instructions for Use Download
Injection Training FAQs pdf Injection Training FAQs Download

Patient Resources

Patient Brochure PDF Patient Brochure Download
FOA & Savings Patient Pamphlet pdf FOA & Patient Savings Pamphlet Download

Answers to common questions about XIPERE® and the SCS Microinjector®

XIPERE treats macular edema (ME) associated with all anatomical locations of uveitis.1

XIPERE is the only treatment approved to deliver medicine via the suprachoroidal space and the first and only uveitic macular edema treatment to demonstrate clinical efficacy with a BCVA primary endpoint.1

The primary endpoint was the number of patients who achieved significant BCVA improvements of 15 or more letters from baseline at 24 weeks.

XIPERE is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, for example1:

  • active epithelial herpes simplex keratitis (dendritic keratitis)
  • vaccinia
  • varicella
  • mycobacterial infections
  • fungal diseases

XIPERE is also contraindicated in patients with known hypersensitivity to triamcinolone acetonide or any other components of this product.

The most common ocular adverse reactions ranged from nonacute elevated IOP (patients treated with XIPERE and patients in the control group were equivalent at a rate of 14%, n=13/96 and n=9/64 respectively) to blurred vision at 2% of patients treated with XIPERE with zero reports in the control group (n=2/96 and n=0/64 respectively).

Please see full adverse events profile under Safety & Tolerability section.

The SCS Microinjector® is composed of a syringe and two 30-gauge hollow microneedles of 900 μm and 1100 μm in free length.1

This suprachoroidal injection is designed to be carried out perpendicular to the sclera under local anesthesia. Once the microneedle penetrates the sclera and reaches the SCS®, the open bevel of the needle releases the drug which spreads to the back of the eye, targeting the tissues of interest.1,2

Yes. Training is highly recommended for the administering specialist.

You can schedule a training session by sharing your name and email address and a local representative will be in touch to arrange.

Have more questions?

Connect with a representative to learn more about XIPERE®.

Reach Out

Eligibility Criteria/Terms and Conditions:

By using the XIPERE copay savings program, you confirm that you understand and agree to comply with the following terms and conditions of this offer:

  • This offer is valid for 12 months from the patient enrollment date.
  • Reimbursement limitations apply. Patient is responsible for all additional costs and expenses after reimbursement limits are reached, including additional copayment and coinsurance amounts.
  • This offer is only valid for eligible patients with commercial insurance and coverage
  • This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs.
  • This coupon shall be applied only toward the patient out of pocket cost for the product and not toward ancillary services or treatment costs.
  • You agree not to seek reimbursement for all or any part of the benefit received through this offer and are responsible for making any required reports of your use of this offer to any insurer or other third party who pays any part of the prescription filled.
  • This offer is good only in the United States of America (including the District of Columbia, Puerto Rico, Guam and the U.S. Virgin Islands).
  • This offer is not valid for any person who is 65 years of age or older without commercial insurance and coverage for the product. You must be 18 years of age or older to redeem this offer.
  • This coupon is good for use only with the products identified herein. No other purchase is necessary.
  • This offer is not valid where prohibited, taxed, or otherwise restricted.
  • This offer is not valid for redemption in the States of California and Massachusetts or by any resident of the States of California or Massachusetts with regard to any product for which a therapeutically equivalent generic product is available.
  • This offer cannot be redeemed at government-subsidized clinics.
  • This coupon and offer are not health insurance.
  • The selling, purchasing, trading, or counterfeiting of this coupon is prohibited by law. Void if reproduced.
  • This offer is not valid with other offers. This coupon has no cash value. No cash back.
  • Bausch + Lomb reserves the right to rescind, revoke, terminate, or amend this offer at any time, without notice.
  • This offer expires December 31, 2022.

 

Indication

XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Important Safety Information

Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.

  • XIPERE is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
  • XIPERE is contraindicated in patients with known hypersensitivity to triamcinolone acetonide or any other components of this product.
  • Use of corticosteroids may produce cataracts, increased intraocular pressure, and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses, and should be used cautiously in patients with a history of ocular herpes simplex.
  • Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and hyperglycemia can occur following administration of a corticosteroid. Monitor patients for these conditions with chronic use.
  • In controlled studies, the most common ocular adverse reactions were increased ocular pressure, non-acute (14%), eye pain, non-acute (12%), cataract (7%), increased intraocular pressure, acute (6%), vitreous detachment (5%), injection site pain (4%), conjunctival hemorrhage (4%), visual acuity reduced (4%), dry eye (3%), eye pain, acute (3%), photophobia (3%), and vitreous floaters (3%), and in 2% of patients: uveitis, conjunctival hyperaemia, punctate keratitis, conjunctival oedema, meibomianitis, anterior capsule contraction, chalazion, eye irritation, eye pruritus, eyelid ptosis, photopsia, and vision blurred.
    The most common non-ocular adverse event was headache (5%).
  • Corticosteroids should be used during pregnancy or nursing only if the potential benefit justifies the potential risk to the fetus or nursing infant.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please click here for full Prescribing Information.

References

  1. XIPERE® [prescribing information]. Alpharetta, GA: Clearside Biomedical, Inc.; 2021.
  2. Yeh S, Khurana RN, Shah M, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology. 2020;127(7):948-955.
  3. Rai Udo J, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495.

Indication

Important Safety Information

XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Important Safety Information

Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.

  • XIPERE is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.

Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.